top of page
PARSIFAL
OFFICIAL TITLE: STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
CLINICAL TRIAL DETAILS
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH HER2 NEGATIVE, ER+ METASTATIC BREAST CANCER.
THIS IS AN INTERNATIONAL, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTICENTER PHASE II CLINICAL TRIAL TO INVESTIGATE AND COMPARE THE SAFETY AND EFFICACY OF PALBOCICLIB COMBINED WITH FULVESTRANT OR LETROZOLE IN WOMEN WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.
PARSIFAL AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
HR+ HER2neg ABC
II
486
50
Spain, France, Italy, UK, Germany, Russia, Czech Republic
N
SITES
COUNTRY
STATUS
Closing
PRESS RELEASE
SCIENTIFIC IMPACT
SABCS 2022 – DOWNLOAD THE POSTER
SABCS 2020 – DOWNLOAD THE POSTER
ESMO 2016 – DOWNLOAD THE POSTER
BLOG ARTICLES RELATED
PARSIFAL SITES
Countries: Spain, France, Italy, UK, Germany, Russia, Czech Republic.
bottom of page